August 2022: Pro aegris adultis cum metastatica non-parva cellula pulmonis cancri (NSCLC) quorum tumores mutationem habent consequens transitum mesenchymal-epithelialem (MET) exon 14 gestientes, ut detectum experimentum FDA probatum, Cibus et Drug Administration capmatinib (Tabrecta dedit. , Novartis Pharmaceutical Corp.) approbatio ordinaria.
Fundata in initiali altiore responsionis rate et duratione responsionis in GEOMETRIA mono-I iudicii (NCT1), multicentri, non temere, patenti pittacii, multi-cohorti inquisitionis, capmatinib antea accelerato probatio eiusdem indicii Kalendis Apr. VI, 02414139. Fundatur notitia ex adiectis 6 aegris et adiectis 2020 mensibus sequentium ad aestimandam responsionem diuturnitatem et beneficium medendi confirmandum, conversio ad approbationem regularium facta est.
160 aegris cum NSCLC progressis cum mutatione omissis exon 14 MET efficaciam ostendit. Aegris capmatinib 400 mg bis die recipitur donec morbus eorum progressus vel effectus latus intolerabilis factus est.
Recognitio Independentis caecata Committee ORR et durationem responsionis (DOR) tamquam mensuras maioris efficaciae (BIRC) decrevit (BIRC). 60 Singuli qui numquam curationem acceperunt 68% ORR (95% CI: 55, 80) et DOR 16.6 mensium (95% CI: 8.4, 22.1). ORR 44% (95% CI: 34, 54) inter 100 aegros qui iam curationem acceperant et DOR menses 9.7 erat (95% CI: 5.6, 13).
The patients’ average age was 71 years (48 to 90). The following specific demographics were reported: 61% female, 77% White, 61% never smoked, 83% had ADENOCARCINOMA, and 16% had metastases to the central nervous system. 81% of patients who had previously had treatment had only gotten one line of systemic therapy; 16% had received two; and 3% had received three. 86% of patients who had previously had treatment had platinum-based chemotherapy.
Aegroti periti edoema, nausea, dolor musculoskeletalis, lassitudo, vomitus, dyspnoea, tussis, et appetitus decrescentes frequentius sunt (20%).
Capmatinib viva voce bis quotidie sumendum in pondere CCCC mg, vel sine prandio.
View full praescribens informationes pro Tabrecta
